Originally Posted by
MAC
We need our DHB managers to be culturally conservative and professional, lives do depend on that.
I don’t think the DHB’s have been slow to pick up Cxbladder one bit and I find such a suggestion by one or two posters to be quite cynical actually.
What Pacific Edge have been pursuing in New Zealand over the last two years with the good and fair assistance of the DHB’s, is product development in parallel with an introductory commercialisation phase for the product, quite ambitious yes, but an overlap is both necessary and pragmatic in bringing a new product to the market.
This has allowed Pacific Edge to work through the clinical trial stage, the US regulatory stage (CLIA), and now the user programme stage of that introductory process.
The user programme studies are only now just complete and the results are due to be presented at the USANZ conference in Brisbane next month, this is likely to be the catalysing point from which the DHB’s and Australian organisations may start to dip their feet in the water and consider the long term regular use of Cxbladder.
Of interest to all the DHB’s will be the Mid Central Health DHB economic evaluation results which are being performed as a 400 test user programme. It must be anticipated by Pacific Edge that this programme should also demonstrate the one third reduction in work up costs.
Onward and forward.